Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.

Hill, RichardMadureira, Patricia AFerreira, BibianaBaptista, InêsMachado, SusanaColaҫo, LauraDos Santos, MartaLiu, NingshuDopazo, AnaUgurel, SelmaAdrienn, AngyalKiss-Toth, EndreIsbilen, MuratGure, Ali OLink, Wolfgang2023-09-042023-09-042023-07-19Nat Commun. 2023 Jul 19;14(1):4341.http://hdl.handle.net/20.500.12105/16396engVoRhttp://creativecommons.org/licenses/by/4.0/Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.Atribución 4.0 Internacional37468494141434110.1038/s41467-023-40050-12041-1723Nature communicationsopen access